Published Materials
Frank I. Navetta, MD, FACC

Publications

• Russell EWB, Weiss LB, Navetta FI. Single channel studies on linear gramicidins with altered amino acid side chains. Effects of altering the polarity of the side chain at position 1 in gramicidin A. Biophysical Journal 186; 49:673-686
• Wehbie CS, Vidaillet JH, Navetta FI, Peter RH. Acute myocardial infarction with initial cocaine use. Southern Medical Journal 1987; 80:933-4
• Navetta, FI, Barber MJ, Gurbel PA. Myocardial ischemia in constrictive pericarditis. American Heart Journal 1988; 116:1107-1111
• Kuehl W, Chu A, Morris K, Navetta FI. Preferential effects of atrial natriuretic peptide (ANP) on proximal and distal coronary arteries in man: Relation to plasma ANP and cyclic guanosine monophosphate (cGMP). Abstract A974; FASEB 1989
• Chu A, Kuehl W, Navetta F. Cobb FR. Preferential effects of atrial natriuretic peptide (ANP) on proximal coronary arteries in man: Relation to plasma ANP and cyclic guanosine monophosphate (cGMP). American Society of Hypertension. Abstract 1989
• Chu A, Morris K, Kuehl W, Cusma J, Navetta F, Cobb FR. Effects of atrial natriuretic peptide on the coronary arterial vasculature in man. Circulation 1989; 80:1627-1635
• Muhlestein JB, Quigley PJ, Navetta FI. Does myocardial damage or hemolysis occur during prolonged perfusion balloon angioplasty. JACC 1990; 15 (Suppl A): 250A
• Smith JE, Navetta FI, Gurbel PA. Can intracoronary urokinase salvage vessel patency after failed I.V.tPA nd prevent the need for rescue PTCA- Abstract. Circulation, 1990; III-537
• Ellis SG, Navetta FI, Tcheng JE. Antiplatelet GP IIb/IIa (7E3) antibody in elective PTCA: Safety and inhibition of platelet function. Abstract. Circulation, 1990; III-191
• Frid DJ, Fortin DF, Navetta FI. Effects of unstable symptoms on restenosis. (Abst). Circ., 1990; III-427
• Jackman JD Jr, Navetta FI, Smith JE. Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris. Am J Cardiol 1991; 68:116-119
• O'Connor CM, Meese RB, Navetta FI, for the DUCCS 1 Investigators. Duke University, Durham, NC. A Randomized Trial of Heparin in Conjunction with Anistreplase (APSAC) in Acute Myocardial Infarction. Abstract. Supplement to Circulation Oct 1991; II-571
• Frid DJ, Navetta FI. The effect of diabetes on restenosis. J Am Col Cardl, Feb. 1991; 17(II, Sup A): p. 268A
• Ellis, SG, Tcheng JE, Navetta FI. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Disease 1993; 4:167-175
• Tcheang JE, Ellis SG, Navetta FI. Duke University Medical Center, Durham, NC. Outcome of Patients Treated with the BPIIb/IIIa Inhibitor Integrelin During Coronary Angioplasty: Results of the IMPACT Study. Circulation, October 1993; 88:1-506
• Tcheng JE, Topol EJ, Navetta FI, EPIC Investigators. Improvement in Clinical Outcomes of Coronary angioplasty by Treatment with the BPIIb/IIIa Inhibitor Chimeric 7E3: Multivariable Analysis of the EPIC Study. Circulation, October 1993; 88:1-506
• Schulman SP, Goldschmidt-Clermont PJ, Navetta FI. John Hopkins Hospital, Baltimore, MD. Integrelin in Unstable Angina: A Dbl-Blind Randomized Trial. Circulation, October 1993; 88:1-506
• O'Connor CM. Meese R, Carney R, Navetta For the DUCCS 1 Investigators. Duke University, Durham, NC. A Randomized Trial of Heparin in Conjunction with Anistreplase (APSAC) in Acute Myocardial Infarction. JACC, 1994
• EPIC Investigators. A Randomized, Dbl-Blind Evaluation of a Chimeric Monoclonal Antibody c7E3 Fab Fragment Directed Against Platelet Glycoprotein IIb/IIIa Receptor for Preventing Ischemic Complications of High Risk angioplasty (EPIC) Investigators. New England Journal of Medicine, April 1994; 956-961
• Tenaglia AN, Fortin DF, Navetta FI. Predicting the Risk of Abrupt Vessel Closure in an Individual Patient. JACC, October 1994; 1004-1011
• Schulman SP, Gottdiener P, Navetta FI. Hopkins Medical Institutions, Baltimore, MD. Rebou Ischemia Does not Occur in Unstable Angina Patients Withdrawn From Integrelin - A Fibrinogen Receptor Antagonist. Circulation, 1994; Vol 90, No. 4;I-372
• Ohman EM, Navetta FI, Carney RJ. For the IMPACT-AMI Study Group, Duke University Medical Center, Durham, NC. Simultaneous Platelet Glycoprotein IIb/IIIa Integrin Blockade with Accelerated Tissue Plasminogen Activator in Acute Myocardial Infarction. Circulation, 1994, Vol 90, No. 4; I564
• Boehrer, JD, Kereiakes DJ, Navetta FI, Califf RM. Effects of Profound Platelet Inhibition w/c7E3 Before Coronary angioplasty on Complications of Coronary Bypass Surgery. Am J Card 1994; 74:1166-1170
• Tcheng JE, Harrington RA, Navetta FI. A Multicenter, Randomized, Double Blind, Placebo Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention. Circulation 1995; (IN PRESS)
• Gurbel, PA, Navetta, FI, Muhlstein, B, Tenaglia, AN, Muller, DW, Bates, ER, Davidson CJ, Miller, MJ, Aquirre, FV, Beauman, GJ, Berdan, JG, Leimberger, JD, Bovill, EG, Christenson, RH, Ohman, EM. Lesion-directed administration of alteplasewith intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. Catheterization and Cardiovascular Diagnosis 1996;37:382-391.
• Schulman, SP, Goldschmidt-Clermont, PJ, Topol EJ, Califf, RM, Navetta, FI, Willerson, JT, Chandra, NC, Guerci AD, Ferguson, JJ, Harrington, RA, Lincoff, AM, Yakubov, SJ, Bahr, RD, Wolfe, CL, Yock, PG, Anderson, HV, Nygaard, TW, Mason, SJ, Effron, MB, Brashears, L, Gottdeiner,P, du Mee C, Kitt, MM, Gerstenblith, G. The effects of integrelin, a platelet glycoprotein Iib/IIIa receptor antagonist in unstable angina: a randomized multicenter placebo-controlled trial. In press.
• Gurbel PA, Navetta FI, Muhlstein B. Combined Intralesional Tissue Plasminogen Activator and Intracoronary Heparin in Patients with Unstable Angina and Coronary Thrombus Undergoing PTCA. Poster Presentation American College of Cardiology. 1995